Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...

Bunzz PTE LTD, a Singapore-based tech company, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating smart ...

You could do worse than to confuse the meanings of "code" and "cipher"—even cryptographers sometime use the terms as though they had the same meaning. There is, however, a definite distinction between ...

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

Bunzz, a Singapore-based web3×LLM tech web3-startup, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating Smart ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier ...

DeCipher is not just a development tool, it envisions something bigger. By providing the vast amount of contract data generated from document creation in a data structure that is easy for AI to read, ...